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Background: Smurf2 is a member of the HECT family of E3 ubiquitin ligases that play important roles in determining
the competence of cells to respond to TGF- β/BMP signaling pathway. However, besides TGF-β/BMP pathway, Smurf2
regulates a repertoire of other signaling pathways ranging from planar cell polarity during embryonic development to
cell proliferation, migration, differentiation and senescence. Expression of Smurf2 is found to be dysregulated in many
cancers including breast cancer. The purpose of the present study is to examine the effect of Smurf2 knockdown on
the tumorigenic potential of human breast cancer cells emphasizing more on proliferative signaling pathway.
Methods: siRNAs targeting different regions of the Smurf2 mRNA were employed to knockdown the expression of
Smurf2. The biological effects of synthetic siRNAs on human breast cancer cells were investigated by examining the
cell proliferation, migration, invasion, focus formation, anchorage-independent growth, cell cycle arrest, and cell cycle
and cell proliferation related protein expressions upon Smurf2 silencing.
Results: Smurf2 silencing in human breast cancer cells resulted in a decreased focus formation potential and
clonogenicity as well as in vitro cell migration/invasion capabilities. Moreover, knockdown of Smurf2
suppressed cell proliferation. Cell cycle analysis showed that the anti-proliferative effect of Smurf2 siRNA was
mediated by arresting cells in the G0/G1 phase, which was caused by decreased expression of cyclin D1and
cdk4, followed by upregulation p21 and p27. Furthermore, we demonstrated that silencing of Smurf2 downregulated
the proliferation of breast cancer cells by modulating the PI3K- PTEN-AKT-FoxO3a pathway via the scaffold protein
CNKSR2 which is involved in RAS-dependent signaling pathways. The present study provides the first evidence that
silencing Smurf2 using synthetic siRNAs can regulate the tumorigenic properties of human breast cancer cells in a
CNKSR2 dependent manner.
Conclusions: Our results therefore suggest a novel relation between Smurf2 and CNKSR2 thereby regulating
AKT-dependent cell proliferation and invasion. Owing to the fact that PI3K-AKT signaling is hyperactivated in various
human cancers and that Smurf2 also regulates cellular transformation, our results indicate that Smurf2 may serve as a
potential molecule for targeted cancer therapy of certain tumour types including breast cancer.
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The execution of cell division with high fidelity is
dependent upon precise spatiotemporal regulation of
posttranslational protein modifications. Recently, a flurry
of papers reported that E3 ubiquitin ligases perform an
integral role in the highly ordered progression of the cell
cycle, and that their deregulation contributes to tumori-
genesis [1,2]. Smurf2 (Smad ubiquitination regulatory
factor 2) is an E3 ubiquitin ligase recently grouped into
the Nedd4 family of HECT ubiquitin ligases that nega-
tively regulates TGF-β signaling [3]. In addition to its
role in TGF-β signaling, Smurf2 functions in diverse bio-
logical pathways, including those controlling the cell
cycle and cell polarity/cytoskeletal remodeling. Smurf2
contains WW domains, which directly bind to a PPxY
motif (also known as PY motif ) in its target. This inter-
action is further stabilized by the PY tail, a six-amino
acid stretch immediately carboxyl terminal to the PPxY
motif, although additional interactions exist [4]. For fur-
ther insight into the cell cycle-regulatory role of Smurf2,
we used a homology-based approach to select for poten-
tial Smurf2 interactors, examining those proteins that
contain a PPxY-motif.
Nonetheless, it was reported that Smurf2 perform a dual
role in cancer by functioning as both tumor promoter and
suppressor by controlling the stability of several important
proteins with central role in cell-cycle progression, prolif-
eration, differentiation, metastasis, genomic stability and
senescence. Notably, aberrant expression of Smurf2 oc-
curs in several types of cancers, including breast, esopha-
geal, pancreatic and renal cell carcinomas. In contrast,
Smurf2 was found to induce senescence and recent mouse
model studies by Blank et al. [5] showed that Smurf2 is a
bona fide tumor suppressor, as the Smurf2-deficient mice
are prone to a variety of cancers, including lymphoma, he-
patocellular, lung and mammary carcinoma. Since Smurf2
is considered to play a contradictory role as tumor pro-
moter and suppressor, understanding the biological func-
tions of Smurf2 and its associated regulatory networks
would be crucial for providing insights into the mecha-
nisms of Smurf-mediated cancer progression and also in
developing therapeutic strategies that target the Smurf
pathway in human cancers [6].
Through their role as a regulator of TGF-β mediated
transcriptional events, Smurfs have been tangentially impli-
cated in the control of the cell cycle. Interestingly, it was
observed that unlike Smurf1 which is expressed constantly
throughout the cell cycle, expression and localization of
Smurf2 itself is cell cycle regulated which accumulates dur-
ing late G2 through early mitosis and is mainly localized to
the centrosome from G1 through prophase, then localizes
to the spindle midzone during anaphase and the midbody
during cytokinesis. This localization pattern of Smurf2 im-
plicates a predominant role for Smurf2 in regulating cellcycle progression. Furthermore, acute depletion of Smurf2
in mammalian cells leads to multinucleation and often ini-
tiates chromosomal misalignment at metaphase and pre-
mature onset of anaphase with defective chromosome
segregation and cytokinesis [1]. It has been shown that
Smurfs regulate the expression of various mammalian pro-
teins that control cell-cycle progression, including Mad2
[1] NEDD9-Aurora A [4,7], RhoA [7], KLF2 [8] and KLF5
[9,10]. All these data strongly support the role of Smurf2 in
tumorigenesis, and subsequently blocking Smurf2 expres-
sion would be a rational strategy to treat breast cancer.
Among various strategies employed to inhibit gene
expression, RNA interference (RNAi) offers significant
promise for cancer therapy due to its ability to potently
knockdown a specific gene. siRNAs of 20 to 25 nucleo-
tides in length silences a target gene by binding to its
complementary mRNA and triggering its degradation
[11-13]. In the present study, we have evaluated the ef-
fect of Smurf2 silencing on colonigenicity, invasive
properties, proliferation, and cell cycle in breast cancer
cells using synthetic siRNA.
Results
Expression of Smurf2 is dysregulated in human breast
cancer tissues and cell lines
In order to explore the role of Smurf2 in carcinogenesis,
we first screened for Smurf2 expression in different can-
cer cell lines by western blot and observed an elevated
expression of Smurf2 in MDA-MB-231 breast cancer
cell line compared to others [6]. Hence, to determine
the appropriate model system for our in vitro study, we
delineated the expression of Smurf2 protein in seven
breast cancer cell lines. As control, we included an un-
transformed but immortalized MCF-10A cell line in the
study. As reported previously [14], we also observed that
Smurf2 expression was decreased in MCF10A cells how-
ever, a strong up-regulation was observed in MDA-MB-
231 cells compared to other cancer cell lines (Figure 1).
Similarly, tissue level expression of Smurf2 was also ana-
lyzed by western blot and it was observed that human
breast IDCs (Infiltrating ductal carcinoma) showed ele-
vated constitutive expression of Smurf2 when compared
to normal counterparts [6]. Together, these results sug-
gested that elevated Smurf2 levels in breast tumours and
cancer cell lines might contribute to the transforming
property of human breast cells.
Silencing of Smurf2 gene by predesigned siRNAs
To silence Smurf2 expression, a mixture of three target
specific 20–25 nt siRNAs targeting different regions of
Smurf2 or the negative control siRNA containing a
scambled sequence which will not lead to the specific
degradation of any known cellular mRNA included in
the kit were transfected to MDA-MB-231 cells at a
Figure 1 Smurf2 is upregulated in human breast cancer cell lines. (A) Smurf2 was found to be specifically upregulated in MDA-MB-231 cell
line compared to other breast cancer cell lines. An untransformed immortalized cell line, MCF-10A was used as the control. β-actin was used to
verify equal gel loading. (B) The bar graph indicates relative levels for Smurf2 protein in cancer cell lines to that in MCF10A. The density of each
Smurf2 signal was normalized by β-actin. Data shows mean value ± S.E. from three independent experiments.
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Smurf2 siRNA showed a significant silencing effect and
knocked down 78% of Smurf2 mRNA in comparison with
control siRNA (Figure 2A). Considering the fact that
siRNA transfection efficiency may vary in different cellFigure 2 Knockdown effect of Smurf2 siRNA in MDA-MB-231 and MC
(siSmurf2) and control siRNA (siControl) at a concentration of 80 pmols. Ce
effect at the Smurf2 mRNA level was determined using real-time RT-PCR. (B
The silencing effect at the Smurf2 mRNA level was measured using real-tim
determined 48 hours post-transfection using western blot in (C) MDA-MB-2lines, we also examined the silencing effect of Smurf2
siRNA in MCF-7 cells. Approximately 69% of Smurf2
mRNA were silenced in MCF-7 cells after treatment
with Smurf2 siRNA (Figure 2B), respectively. The silen-
cing effect of Smurf2 expression at the protein levelF-7 cells. (A) MDA-MB-231 cells were transfected with Smurf2 siRNA
lls were harvested 36 hours after the transfection, and the silencing
) MCF-7 cells were transfected with Smurf2 siRNA, and control siRNA.
e RT-PCR. The silencing effect of Smurf2 siRNA at the protein level was
31 cells and (D) MCF-7 cells.
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significantly inhibited the Smurf2 protein expression in
MDA-MB-231 cells and MCF-7 cells, which is consistent
with the silencing effect at the mRNA level (Figure 2C, D).
Smurf2 silencing inhibits focus formation of breast cancer
cells
First, we used a focus formation assay to test whether si-
lencing Smurf2 in breast cancer cells affects the clono-
genic potential, which correlates with tumor formation
in vivo [15]. Forty-eight hours after transfection, a single-
cell suspension was seeded into six-well plates and incu-
bated for 14 days to allow focus formation. The cells were
fixed, stained with crystal violet, and counted. Foci con-
taining ≥ 50 cells were counted manually. As Figure 3A
shows, MDA-MB-231cells treated with Smurf2 siRNA ex-
hibited smaller focus diameter as well as focus numbers
compared with cells treated with the control siRNA.
However, in MCF-7 cells the effect of siRNA is drastic-
ally increased, causing a considerable decrease both in
focus number and size compared with MDA-MB-231
cells treated with Smurf2 siRNA (Figure 3B). These dataFigure 3 Silencing of Smurf2 inhibits focus formation. Forty-eight hour
were seeded in six-well plates, and the medium was changed every 2 days. C
paraformaldehyde, and stained with 0.5% crystal violet. Images of the colonie
were counted for MDA-MB-231 and MCF-7 cells and the result represented as
siRNA. NC-Negative control without siRNA.indicated that inhibition of Smurf2 significantly decreases
the cells’ focus formation potential, which correlates with
the formation of tumors in nude mice [16].
Anchorage-independent growth of breast cancer cells
hindered by Smurf2 silencing
Anchorage-independent growth in the semisolid medium
of soft agar is a strong indicator of a transformed pheno-
type [16]. In order to examine whether Smurf2 knock-
down can influence the anchorage-independent growth
potential, we performed a soft agar assay in MDA-MB-
231 and MCF-7 cells. Twenty four hours after the trans-
fection, a single-cell suspension was seeded into 0.35%
agarose supplemented with DMEM medium and 10%
FBS. The cells were cultured for another 21 days under
normal cell culture conditions to allow colony formation.
As shown in Figures 4A and C, silencing Smurf2 in MDA-
MB-231 cells dramatically inhibited the transformed
phenotype. Individual colony size was much smaller in
Smurf2 siRNA transfected cells compared with control
siRNA-treated cells. Similar results were also observed in
MCF7 cells (Figures 4B and D). This result indicateds after the siRNA transfection, (A) MDA-MB-231 cells and (B) MCF-7 cells
ells cultured for 14 days were washed twice with 1xPBS, fixed by 4%
s were obtained with a digital camera. (C), (D) Foci containing ≥50 cells
mean ± standard deviation (n = 3). *P < 0.05 compared with control
Figure 4 Smurf2 silencing inhibits colony formation. A soft agar assay was conducted to examine the colony formation ability of (A) MDA-MB-231
cells and (B) MCF-7 cells. Twenty-four hours after the siRNA transfection, MDA-MB-231 and MCF-7 cells were seeded in 0.35% agarose in DMEM medium
supplemented with 10% FBS at a density of 1 × 103 per 35-mm culture dish and allowed to grow for 21 days. The dishes were stained with 0.01% crystal
violet, and the colonies were examined with microscope. Results are representative picture of colonies of two independent experiments done in triplicate.
(C), (D) The number of colonies of MDA-MB-231 and MCF-7 cells were counted and the result represented as mean ± standard deviation (n = 3). *P < 0.05
compared with control siRNA. NC-Negative control without siRNA.
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anchorage-independent growth capability.
Smurf2 silencing impedes cell motility and invasion
Reduced clonogenic potential is usually associated with
the loss of invasion capabilities in tumor cells [15,16].
Therefore, we analyzed the cell motility of breast cancer
cells using a classic wound healing assay in which the
cell monolayer was scratched and cells migrating to the
wound area were monitored at different time points.
Compared with cells transfected with control siRNA, the
cells treated with Smurf2 siRNA showed a wider wound
area 24 hours after wound generation, and took a longer
time to fill in the wound area, indicating a defect in mi-
gration (Figure 5). Since both cell migration and inva-
sion have decisive role in the dissemination of cancer
cells and metastases, we further investigated the cell in-
vasiveness using in vitro migration and invasion assays.
Migration assay was done as described previously [14]
using uncoated Boyden chamber to examine the in vitro
migration ability of tumor cells. Cells that migrated to
the bottom of the transwell were fixed, stained andcounted. Compared with the control group, Smurf2 siRNA
transfected cells showed a significant decrease in the num-
ber of migrated cells in MDA-MB-231 (Figure 6A, C) and
MCF-7 cells (Figure 6B, D). Additionally, matrigel coated
transwell chambers were used to access the invasive poten-
tial of breast cancer cells. Consistent with the finding in
migration assay, MDA-MB-231 (Figure 6A, C) and MCF-7
(Figure 6B, D) cells treated with Smurf2 siRNA exhibited a
significant reduction in cell invasion ability in comparison
with control siRNA-treated cells. Collectively, these results
imply that silencing of Smurf2 decreases the invasive prop-
erties of breast cancer cells.
Downregulation of the proliferative potential in breast
cancer cells post Smurf2 silencing
Carcinogenesis is a multistage process initiated by dis-
turbed and uncontrolled proliferation of cells [17]. In
order to address whether Smurf2 is essential for the prolif-
eration of breast cancer epithelial cells, we next examined
the proliferation rate of breast cancer cells after silencing
of Smurf2 with siRNA. Cell growth was determined at 24,
48 and 72 hours post-transfection. Compared with cells
Figure 5 Smurf2 knockdown impairs cell motility. (A) Wound healing assay was done to evaluate the migration potential of MDA-MB-231
cells after silencing Smurf2 expression. Fifty-six hours after the transfection of siRNA, cells were wounded and monitored with a microscope every
6 hours. (B) The migration was determined by the rate of cells filling the scratched area and the result represented as mean ± standard deviation
(n = 3). NC-Negative control without siRNA.
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Smurf2 siRNAs demonstrated lower viability and slower
growth rate (Figure 7A, B, C, D). Moreover, the inhibition
effect on cell proliferation is more significant at 48 hours
rather than 72 hours posttransfection. Eventhough the
proliferation rate increases slightly after 72 hours post-Figure 6 Silencing of Smurf2 expression inhibits migration and invasi
determined using Boyden transwell chambers. Forty-eight hours after the t
suspended in serum-free medium and seeded on 24-well transwell plates.
were fixed with with 10% formaldehyde, and stained with 0.5% crystal viol
group. Cell invasion was assayed in transwell coated with Matrigel. Invaded
were counted for each group. All experiments were performed in triplicate
invasion was observed after silencing Smurf2 expression in MDA-MB-231 an
MDA-MB-231 and MCF-7 were counted from five or six randomly selected
deviation (n = 3). *P < 0.05 compared with control siRNA. NC, negative contransfection it is significantly lower compared to 24 hours
post-transfection. Furthermore, the inhibitory effect of
Smurf2 on breast cancer cell proliferation was confirmed
by using proliferation markers such as PCNA and Ki67
which are important regulators of proliferative indices
[18]. The expression of PCNA, which increases during theon abilities of MDA-MB-231 and MCF-7 cells. Cell migration was
ransfection with siRNA, (A) MDA-MB-231 cells and (B) MCF-7 cells were
Cells migrated though pores to the bottom surface of the transwell
et and counted. Six random microscopic fields were counted for each
cells were fixed, stained and counted. Six random microscopic fields
s and repeated three times. Significant reduction of migration and
d MCF-7 cells. (C), (D) The number of migrated or invaded cells of
fields in a blind way and the result represented as mean ± standard
trol without siRNA.
Figure 7 Smurf2 knockdown downregulates cell proliferation. Smurf2 knockdown decreases proliferation of MDA-MB-231 and MCF-7 cells
which was measured with an MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay (A, B) and BrdU (5-bromo-2′-deoxyuridine)
cell proliferation assay (C, D). Result represented as mean ± standard deviation (n = 3). The inhibition effect on cell proliferation is more significant
at 48 hours rather than 72 hours posttransfection, after which proliferation gradually increased, probably due to transient transfection. Expression
of PCNA (Proliferating cell nuclear antigen) was found to be downregulated in Smurf2 knockdown cells of (E) MDA-MB-231 and (F) MCF-7,
48 hours posttransfection.
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M-phase of the cell cycle was found to be downregulated
in Smurf2 siRNA treated cells compared with scrambled
siRNA treated cells (Figure 7E, F). Consistently, the ex-
pression of another specific proliferation marker, anti-
gen Ki-67 which is a ubiquitous human nuclear protein
expressed in G1, S, and G2 phases of the cell cycle but
not in the G0-phase was also found to be significantly
downregulated in Smurf2 siRNA treated cells compared
to control siRNA treated cells (Figure 8A, B). These re-
sults suggested the pivotal role of Smurf2 in the prolif-
eration and survival of breast cancer cells, and that
suppression of Smurf2 could lead to downregulation of
cell proliferation.
Smurf2 knockdown induces cell arrest in G0/G1 phase
To identify the mechanism for this anti-proliferation ef-
fect, we investigated the cell cycle distribution of breast
cancer cells after silencing Smurf2 expression in MCF-7
and MDA-MB-231. As shown in Figure 9, cells transfectedwith Smurf2 siRNA induced a significant G0/G1 block in
comparison with cells treated with control siRNA, specific-
ally 48 hours post-transfection. The effect of Smurf2 deple-
tion on cell growth was not due to increased cell death, as
a sub-G0 peak was not detected in Smurf2 siRNA cells. In
addition, we did not observe any profound S or G2-M cell
cycle block in Smurf2-silenced cells. However, a slightly in-
creased number of Smurf2-depleted MDA-MB-231 cells
were consistently identified in G0/G1 at 24, 48 and 72 hours
(64.2%, 76%, and 70.8%), in comparison with cells treated
with control siRNA (66.7%, 73.8%, and 70.5%) (Figure 9A),
which suggested that Smurf2 silencing may have caused
cells to accumulate in G0/G1. In the same experiment, a
comparatively similar result was observed in MCF-7 cells
(Figure 9B). The percentages of cells in the G0/G1 phase
were 58.5%, 70.5%, and 74.7% for cells treated with Smurf2
siRNA at 24, 48 and 72 hours respectively. In comparison,
only 61.8%, 60.9%, and 73.6% of MCF-7 cells treated with
scrambled siRNA at 24, 48 and 72 hours were in the G0/
G1 phase. These findings indicated that Smurf2 depletion
Figure 8 Silencing of Smurf2 downregulates Ki-67 expression. Smurf2 knockdown significantly downregulated the expression of the
proliferation marker Ki-67 in (A) MDA-MB-231 and (B) MCF-7 cells compared to control siRNA treated cells.
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as Smurf2 siRNA markedly inhibited cell proliferation via
blocking cell cycle progression at the G0/G1 phase but had
a negligible effect on cell death.
Cell cycle progression is driven by the oscillating acti-
vation of CDKs alongside precisely timed fluctuations in
the synthesis and degradation of cyclins [19]. SinceFigure 9 Silencing of Smurf2 leads to G0/G1 phase arrest. Cell cycle d
Smurf2 siRNA and control siRNA were accessed by flow cytometry at 24, 48
of three independent experiments, plotting cell count vs. DNA content.cyclin D1 was reported to play a significant regulatory
role during progression through the G1 phase of breast
cancer cells [20], we next examined whether the expres-
sion of cyclin D1 was responsible for the G0/G1 cell
cycle arrest in Smurf2 siRNA-treated cells. As
Figure 10A, B indicates, silencing of Smurf2 significantly
decreased the expression of cyclin D1 in breast canceristribution of (A) MDA-MB-231 cells and (B) MCF-7 cells treated with
, and 72 hours post-transfection. Results are representative histogram
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cyclin B1 remain unchanged. The D-type cyclins are able
to bind to several different CDK partners; Cdk2, Cdk4,
Cdk5 and Cdk6. Of these, their main and consistent
partner appears to be Cdk4 which associates in late G1
and early S phase [20]. Interestingly, we observed that,
in Smurf2 siRNA treated cells, the levels of Cdk4 were
found to be significantly downregulated, in comparison
to control siRNA treated cells. A concomitant decrease
was also observed in the expression levels of Cdk2 and
Cdk1 following Smurf2 knock down in MCF7 and
MDA-MB-231 cells. However, the expression of p27
and p21 cyclin dependent kinase inhibitors (CKIs) were
found to be constitutively elevated following silencing
of Smurf2 in MCF7 and MDA-MB-231 cells. It is
widely accepted that elevated levels of p21cip1 and
p27kip1 induce G1 arrest; therefore, it is highly likely
that the impaired G1-S transition noted in Smurf2-
depleted cells occurs as a result of deregulation of
p21cip1 and p27kip1 levels [17,20]. All together, these
findings suggests that Smurf2 silencing modulates sig-
naling pathways that are integral to G1-S progression,
resulting in constitutively high levels of p21cip1 and
p27kip1 that block cell cycle progression.Figure 10 Expression levels of cell cycle regulatory proteins following
accumulation of cells in the G0/G1 phase. Lysates from (A) MDA-MB-231 an
the indicated antibodies. β-actin was used as the loading control.Depletion of Smurf2 destabilizes CNKSR2
Cell proliferation is regulated by multiple pathways such
as the Raf-MEK-ERK, NF-kB or phosphatidylinositol- 3
kinase (PI3K)-AKT pathways [21]. In order to identify
novel interacting partners of Smurf2 involved in cell
proliferation we used a homology-based approach to se-
lect for potential Smurf2 interactors, examining those
proteins that contain a PPxY-motif. Strikingly, we identi-
fied CNKSR2 (Connector enhancer of kinase suppressor
of ras2) which possess a ‘SPPPPY’ motif at 702–707 se-
quence region that shows a strong PY motif match with
Smurf2 [see Additional file 1: Table S1]. Further studies
using PATHDOCK and GROMACS provided an insight
into the interaction between CNKSR2 and WW domains
of Smurf2. It was observed that WW2 domain of Smurf2
can penetrate more and stabilize with ‘SPPPPY’ motif of
CNSRK2 compared with Smurf2-WW3 domain (Figure 11,
see Additional file 2: Table S2). The possible interaction be-
tween Smurf2 and CNKSR2 has to be further evaluated in
detail. CNK (Connector enhancer of ksr) proteins are evo-
lutionarily conserved scaffold proteins essential for differ-
ent signaling pathways. CNKSR2, the human homolog
most resembling Drosophila CNK, modulates the Raf–
MEK–ERK pathway in neuronal cells and is involved inSmurf2 knockdown. Silencing Smurf2 expression induces
d (B) MCF-7 cells following Smurf2 siRNA treatment were probed with
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the RAS-dependent signaling pathways upstream or in par-
allel to RAF, especially in RAF compartmentalization and
operates in several RTK-mediated developmental events af-
fecting cell proliferation/survival, differentiation and migra-
tion [22].
In our study we observed that Smurf2 knockdown mod-
ulates the level of CNKSR2. In particular, we addressed
whether the E3 ligase Smurf2 would directly target
CNKSR2 for proteasome-mediated degradation. Contrary
to this speculation, it was consistently observed that
CNKSR2 protein levels were decreased by siRNA medi-
ated Smurf2 depletion in MDA-MB-231 and MCF7 breast
cancer cell lines, SW480 colon cancer cell line and
SCC131 oral cancer cell line (Figure 12A). The decline in
CNKSR2 protein levels induced by Smurf2 depletion was
a post-transcriptional effect as qRT-PCR analysis showed
little to no effect on CNKSR2 mRNA level (Figure 12B,
C), suggesting Smurf2 controls the CNKSR2 protein level
possibly through proteolytic regulation. To confirm a role
for Smurf2 in regulating CNKSR2 degradation, we
employed a cycloheximide- based protein degradation
assay. After protein synthesis was blocked by cyclohexi-
mide, CNKSR2 degraded more rapidly in the Smurf2 de-
pleted cells (Figure 12D, E). These results show that
Smurf2 plays an essential role in maintaining the stability
of CNKSR2 protein. To reciprocally establish whether
CNKSR2 controls Smurf2 levels, MDA-MB-231 cells were
transfected with CNKSR2 siRNA. CNKSR2 depletion had
no discernable effect on Smurf2 protein levels (Figure 12F).
These data suggest that Smurf2 positively regulates the
level of CNKSR2 protein at the post-transcriptional level.
Smurf2 regulates cell proliferation through a CNKSR2-
AKT-FoxO3a dependent pathway
The PI3K pathway, activated by receptor tyrosine kinase
growth factors provides proliferative and antiapoptotic
signals and is frequently deregulated and/or activated in
human cancers. The PI3K activity is also required forFigure 11 Smurf2-WW2 domain interacts with CNKSR2. (A), (B) Dockin
coloured) using PATHDOCK and GROMACS indicate that the Smurf2-WW2
‘SPPPPY’ motif (orange coloured) at 702–707 sequence region of CNKSR2, tG1/S phase progression in lymphocytes and in human
mammary epithelial cells (HMECs) [23-25]. AKT is an
important downstream effector of PI3K. AKT regulates
proliferation as well as cell survival and PI3K-AKT sig-
naling is frequently hyperactivated in human tumours
including breast cancer [21]. Since CNKSR2 plays an up-
stream regulatory role in RAS-mediated signaling path-
ways [22,26,27], we analyzed the expression of MEK1/2,
pMEK1/2, ERK1/2, pERK1/2 and NF-kB after Smurf2
knockdown. However, downregulation of CNKSR2 does
not interfere with Ras-MEK-ERK and NF-kB signaling in
MDA-MB-231 cells, which overexpress a constitutively
active Ras molecule. To check whether CNKSR2 influ-
ences AKT activity, we analyzed the phosphorylation sta-
tus of AKT at S473 in MDA-MB-231 cells. This
phosphorylation is crucial for AKT activity [28]. We ob-
served reduced levels of phosphorylated AKT in Smurf2-
knockdown cells (Figure 13). In addition, the expression
of PI3K catalytic subunit p110 was found to be slightly
downregulated in Smurf2 knockdown cells, however there
is not much variation in the expression levels of the regu-
latory subunit p85 which is required for the stabilization
and localization of p110-PI3K activity [29]. AKT fosters
proliferation through phosphorylation of various anti-
proliferative regulators such as FoxO transcription factors.
Results from previous studies have shown that AKT medi-
ated phosphorylation of FoxO3a is critical for its DNA-
binding and transcriptional activity. Specifically, FoxO3a
activity is negatively regulated by AKT, which phosphory-
lates FoxO3a at multiple sites, facilitating its association
with 14-3-3 protein, thereby leading to its transport out of
the nucleus and retention in the cytoplasm thereby pre-
venting FoxO-dependent transcriptional activation and
thus promoting cell proliferation [21,30]. Interestingly, we
observed that Smurf2 knockdown decreased FoxO3a
phosphorylation at S253. However, the expression of total
FoxO3a was found to be slightly upregulated following
Smurf2 knockdown. Impaired Akt activity gauged by the
marked decrease in p-FoxO3a(S253) expression mayg of Smurf2-WW2/3 domains (purple coloured) and CNKSR2 (green
domain shows a better penetration and more stabilization with
han Smurf2-WW3 domain.
Figure 12 Depletion of Smurf2 accelerates degradation of CNKSR2. (A) Depletion of Smurf2 by siRNA (siSmurf2) leads to decreased CNKSR2
protein levels in MDA-MB-231, MCF-7, SW480, and SCC131 cells. (B) Smurf2 does not affect CNKSR2 transcript level. RNA samples from MDA-MB-231
cells transfected with siSmurf2 were analyzed by qRT-PCR and further by (C) RT-PCR for the indicated transcripts. (D) MDA-MB-231 cells transfected
with control siRNA and Smurf2 siRNA were treated with cycloheximide at 100 μg/ml, 48 hours post-transfection. Cells were harvested 0, 1, 2, or 3 h
after cycloheximide addition and the cell lysate was subjected to SDS-PAGE followed by immunoblotting with specific antibodies. (E) Plot of CNKSR2
degradation rate was shown in the panel. (F) CNKSR2 depletion does not affect Smurf2 levels.
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Smurf2 knockdown cells, thereby promoting its tumor
suppressor functions, by upregulating the expression of
FoxO-responsive genes such as p27/Kip1 and p21/waf1.
All these data support the physiological relevance of
CNKSR2 in AKT-dependent regulation of FoxO3a activity
in MDA-MB-231 cells. No significant effect was observed
on the protein levels of total 14-3-3.
Interestingly, we also observed that expression of a po-
tent oncogene, c-Myc was found to be downregulated in
Smurf2 knockdown cells (Figure 13). The c-myc gene is
amplified in various human cancers, acts as a transcrip-
tional regulator, and is overexpressed in many types of
human cancers and is also reported to indirectly inhibit
PTEN expression [31]. Downregulation of c-Myc was
followed by a concomitant increase in the expression of
PTEN (Figure 13) which might be responsible for thedecreased phosphorylation of AKT at S473 which is con-
sistent with the well-established inverse relationship be-
tween MMAC/PTEN expression and AKT activation
[32]. Thus Smurf2 knockdown probably downregulates
proliferation of breast cancer cells in a CNKSR2 dependent
manner by modulating the PI3K- PTEN-AKT-FoxO3a
pathway.
Discussion
Smurf2 plays a decisive role in TGF-β/BMP signaling,
cell migration, cell polarity, differentiation and senes-
cence, mainly by targeting corresponding cellular sub-
strates for ubiquitination and proteasomal degradation.
Smurf2 has been found to be upregulated in several
types of cancer including breast cancer and has been as-
sociated with poor prognosis in esophageal squamous
cell carcinoma and renal cell carcinoma [6]. Our findings
Figure 13 Smurf2 knockdown modulates the PI3K-AKT signaling pathway in a CNKSR2 dependent manner. Smurf2 knockdown
diminishes Akt phosphorylation and FoxO3a-dependent cell proliferation. Lysates from control siRNA and Smurf2 siRNA treated MDA-MB-231 cells
were probed with the indicated antibodies. β-actin was used as the loading control.
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role in the tumorigenesis of breast cancer.
Initially, Smurf2 has been found to play an important
role in cellular transformation by regulating the TGF-β/
BMP signaling, deregulation of which will invariably lead
to developmental defects and/or diseases, including can-
cer [33]. In addition, Smurf2 plays a pivotal role in pro-
liferating cells by controlling various protein complexes,
critical for cell division and growth, such as KLF2, KLF5,
NEDD9-Aurora A etc. [6]. Hence we were interested to
determine the effect of Smurf2 knockdown on prolifera-
tion of breast cancer cells by analysing the focus forma-
tion and colony formation ability in soft agar compared
with cells transfected with the control siRNA. Interest-
ingly, we observed that silencing of Smurf2 with siRNA
led to significant reduction in focus formation and col-
ony formation in both MCF-7 cells and MDA-MB-231
cells (Figures 3 and 4).
Several lines of evidence implicate that Smurf2 and its
interacting partners or substrates are involved in cell inva-
sion and tumour metastasis [6]. Recently, Jin et al. re-
ported that upregulation of Smurf2 promotes metastasis
of breast cancer cells by enhancing migration and inva-
siveness specifically by up-regulating the expression of N-
cadherin which is involved in epithelial-mesenchymal
transition, in a TGF-β/Smad independent manner [14].
Concomitantly, we performed numerous experiments in-
cluding the wound healing assay, migration assay, and in-
vasion assay to assess the effect of Smurf2 knockdown on
invasive potential of MCF7 and MDA-MB-231 breast can-
cer cells. As shown in Figures 5 and 6, the invasivenessproperties were significantly inhibited in cells treated with
the Smurf2 siRNA in comparison with cells treated with
the control siRNA. These data are consistent with the pre-
vious report that inhibition of Smurf2 expression in breast
cancer cells induced a less invasive phenotype compared
with cells transfected with control siRNA.
Smurf2 possess WW domains, which mediate interac-
tions with proteins that have PPxY motifs [34]. In order to
identify novel interacting partners of Smurf2 which may
have crucial role in cell proliferation, we did a homology-
based approach and surprisingly we identified a scaffold
protein CNKSR2 involved in Ras-Raf mediated signaling
pathways. Although the relationship between Smurf2 and
CNKSR2 has not been identified yet, the presence of a
PPxY motif in its structure (SPPPPY motif at 702- 707aa
sequence) predicted a possible interaction between Smurf2
and CNKSR2 [see Additional file 1: Table S1] which was
further confirmed by docking studies between Smurf2-
WW2/3 and CNKSR2 ‘SPPPPY’ motifs [see Additional
file 2: Table S2]. As shown in Figure 11, WW2 domain of
Smurf2 demonstrates a higher penetration and stabilization
with ‘SPPPPY’ motif of CNSRK2 compared with Smurf2-
WW3 domain. Moreover, we observed that depletion of
Smurf2 caused a more rapid degradation of CNKSR2 dur-
ing the cycloheximide chase assay (Figure 12D). This cor-
relation of Smurf2 with CNKSR2 may explain the role of
Smurf2 in proliferation and invasiveness of tumor cells.
Recent studies have shown that downregulation of CNK
(Connector enhancer of KSR) proteins which are scaffold
proteins regulating mitogen-activated protein kinase path-
ways, diminishes the proliferation and invasiveness of
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markably, we also observed that Smurf2 knockdown
caused a considerable downregulation in the expression of
CNKSR2, a CNK homolog, followed by a concomitant de-
crease in the proliferation of breast cancer cells (Figures 7
and 8). To further elucidate the mechanism of this anti-
proliferation effect, cell cycle analysis was conducted. An
accumulation of Smurf2 knockdown cells were observed in
the G0/G1 phase compared with control cells (Figure 9).
All these data strongly suggest the role of Smurf2 in breast
cancer proliferation.
G1–S progression is regulated by the controlled expres-
sion and activity of different cyclins (cyclin D, E and A),
Cdks (Cdk 4, 6 and 2), CKIs (INK4 and cip/kip family of
proteins), Rb protein and E2F transcription factor [36].
Moreover, we observed that expression of cyclin D1, a
critical regulator of G1 phase progression of breast cancer
cells was found to be significantly downregulated in
Smurf2 siRNA treated cells (Figure 10). There is mounting
evidence that cyclin D1 plays a critical role in breast can-
cer cell cycle control. The induction of cyclin D1 in breast
cancer cells shortens the G1 phase and increases the num-
ber of cells that progress through the G1 phase, resulting
in an increased proliferation [20]. In mammalian cells, the
cyclins associate with specific cyclin-dependent kinases
such as Cdk2, Cdk4, and Cdk6 which are key regulators of
G1 to S phase transition [37]. In our study we observed
that expression of Cdk4, one of the consistent partners of
cyclin D1 was found to be inhibited in cells treated with
Smurf2 siRNA, followed by a concurrent downregulation
in the expression of Cdk1, pCdk1 and Cdk2. Besides
cyclins and Cdks, the cyclin-dependent kinase inhibitors
(CKIs), specifically, the Cip/Kip family CKIs such as p21
WAF1/CIP1 and p27 KIP1 regulates G1-S phase progression
by inhibiting the cyclinD-cdk4/cdk6 association [37]. Con-
sistently, our studies have shown that Smurf2 knockdown
caused a marked upregulation in the expression of p21
and p27 thereby promoting accumulation of cells in the
G1 phase (Figure 10).
The PI3K/AKT-signaling pathway regulates proliferation
as well as cell survival and is constitutively activated in
various human cancers, including breast cancer. An accu-
mulation of evidence supports a key role for the PI3K
pathway in cell cycle progression especially during the G1-
S transition. A key effector of this pathway is AKT [5,21].
Fritz et al. reported that CNKSR2, the human homolog
most resembling Drosophila CNK, modulates the Raf–
MEK–ERK and NF-kB pathways in neuronal cells. The
role of hCNKSR2 in RTK-mediated events has been exam-
ined in PC12 cells. Interestingly, knockdown of hCNK2 in
PC12 prevented NGF-dependent ERK activation as well as
neurite outgrowth. It thus appears that CNK proteins can
mediate RTK-specific signals and that their function is not
restricted to RAS/ERK signaling [35]. In our study weobserved that downregulation of CNKSR2 expression fol-
lowing Smurf2 knockdown did not affect the MEK, ERK
and NF-kB signaling cascades. However, there is a marked
reduction in the expression of pAKT(S473) and total AKT
levels. In addition, the PI3K catalytic subunit p110 was
found to be moderately downregulated in Smurf2 knock-
down cells, however there is not much variation in the ex-
pression levels of the regulatory subunit p85 which is
required for the stabilization and localization of p110-PI3K
activity (Figure 13).
Liang et al. reported that proteolysis of c-Myc and cyclin
D1, which play distinct roles in cell cycle progression
through G1 phase is regulated by the PI3K-AKT pathway.
The stability of c-Myc is controlled by phosphorylation at
S62 and T58 in a hierarchical fashion and AKT activation
would stabilize c-Myc through inhibition of GSK-3β
mediated T58 phosphorylation thereby protecting it
from ubiquitin dependent degradation. In addition overex-
pression of constitutively active AKT was shown to extend
the half-life of cyclin D1 protein whereas PI3K inhibition
accelerated cyclin D1 degradation [25]. Consistently, we
also observed that Smurf2 mediated CNKSR2 dependent
downregulation of AKT activation caused inhibition of ac-
tivation of c-Myc and cyclin D1 (Figure 13) thereby pro-
moting accumulation of Smurf2 knockdown cells in the
G0/G1 phase. Recently, Guo et al. reported that c-Myc
can indirectly inhibit PTEN expression in GBM cells,
thereby promoting proliferation. MMAC/PTEN phos-
phatase is a critical mediator of PI3K-AKT signaling that
dephosphorylates the phosphoinositide products of PI3-
kinase and functions as its natural antagonist [31,32]. In
our study we observed that downregulation of c-Myc was
followed by a concomitant increase in the expression of
PTEN (Figure 13) which might be responsible for the de-
creased phosphorylation of AKT at S473 which is consist-
ent with the well-established inverse relationship between
MMAC/PTEN expression and AKT activation.
PI3K-AKT promotes cell survival by indirectly regulating
the phosphorylation of various downstream signaling and
target molecules including the mammalian forkhead box
subgroup ‘O’ (FoxO) of forkhead transcription factors con-
sists of FoxO1, FoxO3a, FoxO4 and FoxO6 which play an
important role as tumor suppressor in several human ma-
lignancies. Specifically, FoxO3a activity is negatively regu-
lated by AKT, which phosphorylates FoxO3a at multiple
sites, facilitating its association with 14-3-3 protein, thereby
leading to its transport out of the nucleus and retention in
the cytoplasm. The cytosolic retention of FoxO3a prevents
the transactivation of downstream target genes such as
p27/Kip1 [30]. We hypothesized that inhibition of AKT
phosphorylation mediated by downregulation of expres-
sion of CNKSR2 in Smurf2 knockdown cells would lead
to nuclear sequestration of FoxO3a and increased tran-
scription of responsive genes. Studies have shown that
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which correlates with upregulation of p27/Kip1 [30]. In
agreement with the hypothesis, our results demonstrate
that Smurf2 knock down caused an upregulation in the
expression of FoxO3a. However, the expression of phos-
phorylated FoxO3a(S253) was decreased after Smurf2
knock down resulting in the nuclear retention of these
proteins and increased transcription of responsive genes
such as p27/Kip1 (Figure 13).
Together, these data suggest that Smurf2 knockdown
modulates the proliferation and invasiveness of breast
cancer cells via regulating the PI3K-AKT signaling path-
way and its downstream targets in a CNKSR2 dependent
manner. Increased levels of CNK homologs have been
identified in various cancers including breast cancer [27].
CNK1 was identified as one of a few critical genes that
mediate metastasis in breast cancer [35]. However, the
functional significance and regulation of CNKSR2 which
is specifically involved in neuronal differentiation has not
been fully identified yet. In our study, we report for the
first time that Smurf2 knockdown caused a marked de-
crease in the expression of CNKSR2 which in turn down-
regulates the proliferation and invasiveness properties of
breast cancer cells via the PI3K-AKT signaling cascade. It
will be important to determine whether Smurf2 can inter-
act with CNKSR2 which possess a PPxY sequence in its
structure which is necessary for interaction with WW do-
main of Smurf2 [34] and whether its levels correlate with
each other in human breast cancer progression models.
Future studies using human cancer specimens should pro-
vide insight into the putative oncogenic interaction of
these two proteins in the regulation of cell cycle progres-
sion and cell proliferation of breast cancer cells.
Conclusions
In summary, studies from our laboratory have shown
that silencing of Smurf2 with siRNA resulted in signifi-
cant inhibition of focus formation potential, anchorage-
independent growth capability, migration, invasiveness,
and proliferation in breast cancer cells by a possible
interaction with CNKSR2. The expression of CNKSR2, a
multi-functional scaffold protein involved in Ras-Raf sig-
naling cascade was inhibited following Smurf2 knockdown
which modulates the PI3K-AKT signaling pathway and its
downstream molecular targets involved in cell prolifera-
tion and invasiveness. We therefore conclude that target-
ing the Smurf2-CNKSR2- PI3K/AKT functional axis could
be used as a potential preventive/therapeutic strategy in
the management of breast cancer in humans.
Methods
Cell lines and culture conditions
All human breast cancer cell lines (MCF 10A, MCF-7,
MDA-MB-231, MDA-MB-435, T-47D, NCI/ADR-RES,SK-BR3 and Hs578T) were purchased from the ATCC
(Rockville, MD). MCF10A cells were cultured in DMEM/
F12 supplemented 10% FBS, 20 ng/ml EGF, 100 ng/ml
cholera toxin, 0.01 mg/ml insulin, and 500 ng/ml hydro-
cortisone and all other cell lines were maintained in
DMEM medium supplemented with 10% FBS, penicillin
(100unit/ml), and streptomycin (100 μg/ml) and were cul-
tured at 37°C in a humidified atmosphere containing 5%
carbon dioxide. The culture medium was changed every
other day and the cells were passaged when they reached
80 to 90% confluency.
siRNA -directed gene knockdown
Cells were transfected with siRNA against Smurf2, in the
form of a mixture of three target specific 20–25 nt siRNAs
targeting different regions of Smurf2 (41675, Santa Cruz
Biotechnology) or the negative control siRNA (37007,
Santa Cruz Biotechnology) included in the kit and siLent-
Fect (170–3361, Bio-Rad) according to the manufacturer’s
instructions. Briefly, cells were seeded in a 6 well plate at a
density of 2 × 105 cells/well in 2 ml antibiotics-free normal
growth medium supplemented with FBS medium 24 h be-
fore the transfection. Eight microliters (80 pmols) of the
siRNA were mixed with 2 μl siLentFect in 200 μl Opti-
MEM (Gibco/Invitrogen) medium and were incubated at
room temperature for 45 min to form a complex. After
washing cells with Opti-MEM, the 200 μl transfection mix-
tures were added to each well with 800 μl Opti-MEM
medium. Twenty-four hours after the transfection, the
medium was replaced with fresh DMEM medium contain-
ing 10% FBS. Cells were collected at 36 or 48 h for RNA or
protein isolation.
Reverse transcriptase -PCR
Total RNA was isolated using TRIzol (Invitrogen) re-
agent according to the manufacturer’s protocol. 10 μg of
total RNA was converted to cDNA using oligo-dT pri-
mer and M-MLV Reverse Transcriptase (Promega) in a
25 μl reaction. The RT-PCR reaction mixture contained
5 μl of 10× reaction buffer, 2 μl of cDNA template, 1 μl
each of forward and reverse primers, and 0.5 μl of Taq
DNA polymerase (Sigma) in a final volume of 20 μl. The
reaction was done at 94°C for 5 min (Initial denatur-
ation), 94°C for 45 s (Denaturation), 60°C for 1 min (An-
nealing), 72°C for 45 s (Extension), and 72°C for 5 min
(Final extension) for 35 cycles. Analysis of amplified
products was done on 2% agarose gel and visualized
using Fluor-S™ MultiImager (Bio-Rad). The PCR prod-
ucts were quantified by densitometric analysis, using
Bio-Rad Quantity One software. A 100-bp ladder (New
England Biolabs) was used as a size standard. The
primers used for the study included: Smurf2, 5′-
CGCTTGATCCAAAGTGGAAT-3′ (forward) and 5′-
GGTTGATGGCATTGGAAAGA-3′ (reverse); CNKSR2,
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TGAGCAAATGGTCTCCGAGT-3′(reverse). GAPDH was
used as an internal control and the primers used were
5′-TTAAAAGCAGCCCTGGTGAC-3′ (forward) and 5′-
CTCTGCTCCTCCTGTTCGAC-3′ (reverse).
Quantitative RT-PCR
Quantitative real-time RT-PCR was performed as de-
scribed previously [9]. Total RNA was isolated from cells
using TRIzol reagent (Invitrogen) according to the man-
ufacturer’s protocol. Total RNA (2 μg) was converted to
cDNA using oligo dT primer and M-MLV Reverse Tran-
scriptase (Promega). One hundred nanograms of cDNA
was amplified and detected with the Power SYBR Green
PCR Master Mix (Applied Biosystems) on an ABI
7900HT Fast Real-Time PCR System (Applied Biosys-
tems). To confirm the PCR specificity, PCR products
were subjected to a melting-curve analysis. The com-
parative threshold method was used to calculate the
relative amount of mRNA of treated sample in compari-
son with control samples after normalization with the
GAPDH control. The primers used for the study in-
cluded: Smurf2, 5′-TGGATCAGGAAGTCGGAAAA-3′
(forward) and 5′- GGACATGTCTAACCCCGGA-3′(re-
verse); CNKR2, 5′- AACCGGTGAGCAAATGGTCT-3′
(forward) and 5′-CCTGATGTGTAATGCGCAGC-3′
(reverse). We used GAPDH as an internal control and the




The cultured cells were washed twice with ice-cold PBS
and lysed on ice in lysis buffer comprising 10% NP40, 5 M
NaCl, 1 M HEPES, 0.1 M DTT, 0.1 M EGTA, 0.1 M
EDTA, protease inhibitors (Sigma) and differential centri-
fugation (14000 rpm for 10 minutes). The amount of total
protein was determined using Bradford’s assay (Bio-Rad).
An equal amount of total protein (60 μg) was loaded and
separated by SDS-PAGE. The separated proteins were
electrotransferred onto nitrocellulose membrane (Amer-
sham Pharmacia Biotech), blocked with 5% skimmed milk
and probed with appropriate antibodies. The protein was
then visualized using horseradish peroxidase-conjugated
secondary antibodies (Santa Cruz Biotechnology) and im-
munoreactive bands were developed with an ECL system
(Amersham Pharmacia Biotech) and quantified using
Image Lab Software version 4.1(BIO RAD). The anti-
bodies used were Smurf2(H-50), cyclin D1(A-12), cyclin A
(BF683), cyclin E(C-19), cyclin B1, cdk4(B-10), p21(187),
p27(C-19), MEK1/2(12B), ERK1/2, NF-kBp65(C-20), IkB-
α(H-4), c-Myc(9E10), PTEN(B-1), PI3Kp110, Goat anti-
rabbit IgG, and Goat anti-mouse IgG from Santa Cruz
Biotechnology (Santa Cruz, California); Cdk2, pMEK1/2(S217/221), pERK1/2(Thr202/Tyr204), Akt, pAkt(S473),
14-3-3, FoxO3a(75D8), pFoxO3a(S253) from Cell Signal-
ing Technology (Beverly, Massachusetts); CNKR2 from
Abcam (Cambridge, UK); PI3Kp85 from BD Biosciences
(New Jersey, USA); and b-Actin (Clone AC-15) from
Sigma Aldrich (St. Louis, USA).
Cycloheximide chase assay
A cycloheximide chase assay was performed as described
[9]. Briefly, MDA-MB-231 cells were transfected with
Smurf2 siRNA or nontargeting siRNA 48 h before the
experiment. Cycloheximide (Sigma) was added to the
cells at 100 μg/ml final concentration. Cells were har-
vested 0, 1, 2, or 3 h after cycloheximide addition and
the cell lysate was subjected to SDS-PAGE followed by
immunoblotting with specific antibodies.
MTT assay
Cell proliferation was examined by MTT assay. Briefly,
MDA-MB-231 cells were seeded at a density of 5 × 103
cells/well in 96-well plates in triplicate, each contained
100 μl of medium.
At different times (24, 48, and 72 h), after Smurf2
siRNA transfection, cells were incubated with 10 μl of
5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT; Sigma) diluted in PBS at 37°C.
Four hours later, 200 μl of isopropanol was added to the
MTT treated wells and the absorption at 570 nm was
determined using a benchmark microplate reader (Bio-
Rad).
BrdU incorporation assay
A BrdU cell proliferation assay was performed according
to the manufacturer’s instructions. MDA-MB-231 cells
(2 × 104 cells/well) were incubated in 96-well plates each
contained 100 μl of medium. At different times (24, 48,
and 72 h), after Smurf2 siRNA transfection, cells were
incubated with 30 μM 5-bromo-2′-deoxyuridine (BrdU;
Sigma) for 30 min at 37°C. Cells were fixed and perme-
abilized with methanol, treated with HCl, neutralized,
and blocked with 2% BSA in PBS. Cells were then incu-
bated with mouse anti-BrdU (70443, Santa cruz Biotech-
nology), FITC-conjugated anti-mouse (2010, Santa cruz
Biotechnology). The absorbances of the wells were read
at 520 nm on an automatic microplate reader (TECAN
infinite 200).
Clonogenic assay
Smurf2 knockdown MDA-MB-231 cells and control
transfected cells (1x103 cells/well) were seeded in six-
well plates in DMEM/5% FBS. The medium was chan-
ged every 2 days. Cells cultured for 14 days were washed
twice with 1xPBS, fixed by 4% paraformaldehyde, and
stained with 0.5% crystal violet and colonies containing
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counted manually. Images of the colonies were obtained
using a digital camera. The experiments were done in
duplicate at least three times.
Soft agar assay
Colony formation ability was examined by anchorage in-
dependent soft agar assay on MDA-MB-231 and MCF7
cells. Briefly, 1.5 ml FBS supplemented medium contain-
ing 0.8% agarose were added in 35-mm cell culture
dishes and allowed to solidify (base agar). Next, 1×103
Smurf2 knockdown MDA-MB-231 and MCF7 cells were
mixed with 1.5 ml FBS supplemented medium contain-
ing 0.35% agarose and added to the top of base agar.
The cells were then cultured for 21 days at 37°C under
5% carbon dioxide. The dishes were stained with 0.01%
crystal violet, and the colonies were examined with
microscope. The experiments were done in triplicate at
least two times.
Wound healing assay
MDA-MB-231cells seeded in 12-well plates (2 × 105
cells/well) were transfected with Smurf2 siRNA as de-
scribed above. Once the cells reached 90% confluency, a
wound area was carefully created by scraping the cell
monolayer with a sterile 100 μl pipette tip. After being
washed three times with PBS, scratches including the
flanking front lines of cells, were photographed (20-fold
magnification). Subsequently, the cells were incubated at
37°C in 5% CO2. The width of the wound area was mon-
itored with an inverted microscope at various time
points. Wound closing was compared between Smurf2
knockdown cells and control transfected cells after
measuring the wound width and evaluated using Leica
application Suite software (LASV3.8, Germany). Differ-
ences between the data points were determined by Stu-
dent’s t test where p < 0.05 was considered significant.
Experiments were performed independently two times,
evaluating 4 – 8 scratches in each experiment.
Migration and invasion assay
Cell migration and invasion assay was done as described
previously [14]. Briefly, MDA-MB-231 cells were seeded
at 2×105 cells/well in 6-well format and transfected by
Smurf2 siRNA as above. Forty-eight hours after the
transfection, the cells were trypsinized and resuspended
in FBS-free DMEM medium. For the migration assay, a
total of 1 × 105 cells were added to the top chamber of
pre-wet transwell inserts (BD Falcon™ 8 μm Control in-
sert). For the invasion assay, 1 × 105 cells were plated in
the top chamber of matrigel-coated transwell inserts
(BD Falcon™ 8 μm Control insert). Complete culture
media with 10% FBS was added to the lower chamber as
a chemoattractant. After incubation for 16 h (migrationassay) or 24 h (invasion assay), cells were washed, fixed
with 10% formaldehyde for 20 min, and stained with
0.5% crystal violet. Cells that did not migrate through
the pores were mechanically removed by a cotton swab.
The images of migrated cells were acquired by an
inverted microscope with a magnification of 200×. The
number of migrated or invaded cells was counted from
five or six randomly selected fields in a blind way. All
migration experiments were performed in triplicates and
repeated three times.
Cell cycle analysis
Cell cycle distribution after Smurf2 knockdown was car-
ried out at indicated times. Cells were harvested and
fixed with ice-cold 70% ethanol and precipitated over-
night at 4°C. After fixation, cells were resuspended in
room temperature PBS, treated with RNase A (100 μg/
ml), and incubated for 1 h at 37°C followed by treatment
with propidium iodide (10 μg/mL), in the dark, for
15 min. Finally, DNA content of the cells was analyzed
using FACS Aria (Special order system, BD, USA).
Immunofluorescence
Cells at 60% confluence were plated onto sterilized glass
coverslips. The slides were washed in phosphate-buffered
saline (PBS) and fixed for 20 min in ice-cold acetone/
methanol (1:1) on ice. The slides were then blocked with
3% BSA in PBS for 1 hour at 37°C, followed by incubation
with anti-Smurf2 (25511, Santa cruz Biotechnology), anti-
Ki67 (H300, Santa cruz Biotechnology), FITC-conjugated
anti-rabbit, and PE-conjugated anti-mouse (2012, Santa
cruz Biotechnology) antibodies. Cells were also stained
with Hoechst dye (Hoechst 33342, Invitrogen) to reveal
nuclei. The images were taken at × 60 magnification using
a confocal microscope (FV1000 Olympus).
Homology based approach to predict novel interacting
partner of Smurf2
There are many different computational approaches to
predict protein interactions; some are based on genomic
context, co-evolution, co-expression or co-occurrence
patterns of potentially interacting partners. In order to
predict novel direct interaction partners for Smurf2, we
used a simple homology based approach [38]. We first
used four known interactors of Smurf2 (Smad2, Smad6,
Smad7, and NDFIP1) and extracted the sequences and
carried out a secondary structure prediction. We then
wrote a Perl script that searched for sequences in Uni-
prot that most closely matched the known Smurf2 bind-
ing motif containing the PY motif and had the same
secondary structure neighborhoods as the identified
ones. BLASTp with p-value cut-off of 0.01 was used for
sequence based searches and 3D-PSSM was used for
secondary structure assignment. Details of the test cases
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sensus and the predicted protein interaction partners are
given (see Additional file 1: Table S1). The locations of
the PY motif, known to be involved in WW domain bind-
ing are also shown. We included only those proteins that
matched both criteria of a secondary structural match
(beta-strand flanking region or having no secondary struc-
ture) and a strong PY motif match.
The ‘SPPPPY’ motif of CNKSR2 was modeled by sub-
mitting the sequence to I-TASSER prediction server and
Patchdock, which detects shape complimentary of mo-
lecular surfaces was used determine the interaction be-
tween CNKSR2 and Smurf2 WW2/3 domains. The
scoring is based on the distance of ligand atoms from the
protein surface, close atoms receive a positive score, and
penetrating atoms receive a negative score, respective to
penetration depth. The docking was performed focusing a
specific area of the CNKSR2 (‘SPPPPY’ motif) by men-
tioning the residues in the parameter file. Out of all the
solutions generated by Patchdock, the one having the
highest score proceeded to the simulation studies. OPLS-
AA(2001) forcefield in Gromacs 4.5.4 was used for simu-
lating the CNKSR2- Smurf2WW2/3 complexes. The com-
plexes were placed in a water box. All runs were at 300 K
with a time step of 2 fs. All bonds were constrained using
the LINCS algorithm. The simulation was performed for
500 ps. The energy analysis was done using the tools avail-
able in GROMACS package.
Statistical analysis
Data were expressed as the mean ± standard deviation.
Difference between any two groups was determined by
analysis of variance. P < 0.05 was considered statistically
significant.
Additional files
Additional file 1: Table S1. Homology based prediction of Smurf2 and
CNKSR2 interaction. CNKSR2 possess a ‘SPPPPY’ motif at 702–707 sequence
region that shows a strong PY motif match with the WW domain of Smurf2
compared with other known interacting partners such as Smads (Smad2, 6
and 7) and NDFIP1(Nedd4 family interacting protein 1).
Additional file 2: Table S2. Smurf2 WW2/3 and CNKSR2 ‘SPPPPY’
domain docking. Docking of Smurf2 WW2/3 and CNKSR2 ‘SPPPPY’
domains using PATHDOCK and GROMACS indicates that CNKSR2-
Smurf2WW2 docking shows highest score, area of interaction and more
penetration and stabilization (less energy) with ‘SPPPPY’ motif (702–707
sequence) of CNSRK2 compared with CNKSR2-Smurf2WW3 docking.
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